China Resources Double Crane : La filiale Ganluolin Injection a obtenu la notification d'approbation de la demande complémentaire de médicament

2026-04-10 03:17:08

China Resources Shuanghe announces that its wholly-owned subsidiary Xi’an Jingxi Shuanghe Pharmaceutical Co., Ltd. has received the “Notice of Approval for the Supplementary Application of the Drug” from the National Medical Products Administration for Mannitol Injection, approving an additional specification of 3000ml:150g.
Mannitol injection, as a rinse, is used for intraurethral surgical rinsing to clear the visual field.
Jingxi Shuanghe’s current Mannitol injection is 250ml:50g, and the company initiated the specification increase research in May 2023, submitted the application on August 15, 2024, and received approval on March 31, 2026.
The company’s total R&D investment in this drug amounts to RMB 1.4491 million.

Voir l'original

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.